SRRA - Sierra Oncology, Inc.
0.4035 -0.00 (-0.76%)
Pre-Market: 8:59AM EST
| Previous Close | 0.4230 |
| Open | 0.4236 |
| Bid | 0.4051 x 800 |
| Ask | 0.4435 x 800 |
| Day's Range | 0.4000 - 0.4300 |
| 52 Week Range | 0.2160 - 2.0100 |
| Volume | 1,288,881 |
| Avg. Volume | 2,198,930 |
| Market Cap | 30.368M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7390 |
| Earnings Date | Feb 25, 2020 - Mar 01, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.90 |
- GuruFocus.com
5 More Deep-Value Stocks for 2020
More companies to consider for the new year that are trading at a discount to net-net working capital Continue reading...
- Insider Monkey
Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- PR Newswire
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today reported new analyses of Phase 3 clinical data highlighting the anemia related benefits of momelotinib directly compared to ruxolitinib, which were presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
- CNW Group
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
VANCOUVER , Dec. 2, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Event on Sunday, December 8 th at 7:00 am ET to discuss newly reported clinical data for momelotinib that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida . The event will be led by Dr. Nick Glover , President and CEO of Sierra Oncology, and will include a presentation by renowned myelofibrosis expert, Dr. Ruben Mesa , Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.
- PR Newswire
Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million.
- PR Newswire
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
VANCOUVER, Nov. 20, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis. The randomized double-blind global Phase 3 trial is designed to confirm the efficacy of momelotinib on myelofibrosis symptoms, transfusion independence and splenomegaly, as compared to danazol.
- PR Newswire
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building Momentum for Patients with Myelofibrosis" at the Jefferies 2019 London Healthcare Conference in London, United Kingdom. Sierra Oncology is a late stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Momelotinib, Sierra's lead drug candidate, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements, a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, and comparable spleen control to ruxolitinib.
- PR Newswire
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has agreed to amend its Asset Purchase Agreement with Gilead Sciences, Inc. for momelotinib upon Sierra closing a qualified financing. "These are significant amendments that meaningfully enhance the potential long-term value of momelotinib for Sierra and its stockholders.
- PR Newswire
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the pricing of an underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with expected gross proceeds to Sierra Oncology of $103 million. The offering is comprised of 103,000 shares of Series A preferred stock, 312,090,000 Series A warrants to purchase up to an aggregate of 312,090,000 shares of common stock at an exercise price equal to $0.33 per underlying share of common stock, and 312,090,000 Series B warrants to purchase up to an aggregate of 102,989,700 shares of common stock at an exercise price equal to $0.33 per underlying share of common stock.
- CNW Group
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants
VANCOUVER , Nov. 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it intends to offer and sell shares of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, in an underwritten public offering. All of the securities to be sold in the offering will be offered by Sierra Oncology. Sierra Oncology intends to use the net proceeds from the public offering to fund MOMENTUM, its planned Phase 3 clinical trial of momelotinib, as well as for general corporate purposes.
- CNW Group
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
VANCOUVER , Nov. 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that new analyses of RBC transfusion data from SIMPLIFY-1, a double-blind Phase 3 trial of its investigational drug momelotinib vs ruxolitinib in JAK inhibitor naïve patients, will be presented in a poster at the 61st American Society of Hematologists (ASH) Annual Meeting in Orlando, Florida .
- PR Newswire
Sierra Oncology Reports Third Quarter 2019 Results
- MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER , Nov. 4, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on ...
- Simply Wall St.
Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?
The big shareholder groups in Sierra Oncology, Inc. (NASDAQ:SRRA) have power over the company. Institutions will often...
- CNW Group
Sierra Oncology Reports Second Quarter 2019 Results
Sierra Oncology Reports Second Quarter 2019 Results
